Mark recently has spoken about broadening the trials ,who better than Merck’s ,(Keytruda) which appears to be less toxic ,then other competitors drugs to broaden the trials with in new indications A doubling of responses with no added toxicity ,servicing a larger market (all comers),with the current world leading immunotherapy drug ,nearing its patent cliff.This has to be a no brainer,Merck stands to gain more ,by paying a premium to partner with exclusive rights.Barring other current deals already in place,ie, EOC ,Novartis,Pfizer etc…
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-24
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $1.515M | 3.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 115519 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 37481 | 2 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |